Loniten Related Published Studies
Well-designed clinical trials related to Loniten (Minoxidil)
Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. [2009.08]
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. [2007.11]
A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. [2007.01]
K+ channel activation with minoxidil stimulates nasal-epithelial ion transport and blunts exaggerated hypoxic pulmonary hypertension. [2006.03]
Treatment of anal fissures using a combination of minoxidil and lignocaine: a randomized, double-blind trial. [2005.07]
Well-designed clinical trials possibly related to Loniten (Minoxidil)
Pharmacotherapy review of chronic pediatric hypertension. [2011.10]
Topical treatment and combination approaches for vitiligo: new insights, new developments. [2010.02]
Alopecia areata update: part II. Treatment. [2010]
Efficacy of combination therapy for the management regime of Alopecia areata. [2007.07]
Other research related to Loniten (Minoxidil)
Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind,
placebo-controlled, spilt-face comparative study. [2014]
Comparison of the efficacy of topical minoxidil 5% and adenosine 0.75% solutions
on male androgenetic alopecia and measuring patient satisfaction rate. [2013]
Preparation and evaluation of a multimodal minoxidil microemulsion versus
minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a
pilot study. [2013]
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. [2011.12]
Transcutol containing vesicles for topical delivery of minoxidil. [2011.04]
Very large incidental pericardial effusion attributable to minoxidil: resolution without drainage. [2011.03]
Follicular and percutaneous penetration pathways of topically applied minoxidil foam. [2010.11]
In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl beta-cyclodextrin/minoxidil complex. [2010.06.15]
Improvement in physicochemical parameters of DPPC liposomes and increase in skin permeation of aciclovir and minoxidil by the addition of cationic polymers. [2010.06]
Minoxidil-associated exudative pleural effusion. [2010.05]
Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman. [2010.04]
Inhibition of isolated human myometrium contractility by minoxidil and reversal by glibenclamide. [2010.03]
Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro. [2010.02]
Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. [2009.10.01]
Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. [2009.07.30]
Fatal toxic epidermal necrolysis associated with minoxidil. [2009.04]
Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. [2009.03]
Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin. [2009.02]
After-rinsing hair growth promotion of minoxidil-containing amino alpha-cyclodextrins. [2007.12]
Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. [2007.05]
Promotive effect of minoxidil combined with all-trans retinoic acid (tretinoin) on human hair growth in vitro. [2007.04]
Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. [2007.02]
Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. [2007.02]
The additive effects of minoxidil and retinol on human hair growth in vitro. [2007.01]
Stevens-Johnson syndrome associated with oral minoxidil: a case report. [2007.01]
Efficacy of 5% Minoxidil versus Combined 5% Minoxidil and 0.01% Tretinoin for Male Pattern Hair Loss : A Randomized, Double-Blind, Comparative Clinical Trial. [2007]
Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice? [2007]
Effect of tocopheryl polyethylene glycol succinate on the percutaneous penetration of minoxidil from water/ethanol/polyethylene glycol 400 solutions. [2006.06]
Does the hyperfiltration of minoxidil result in increased proteinuria and loss of renoprotection conferred by angiotensin inhibition? [2006]
Simultaneous effects of tocopheryl polyethylene glycol succinate (TPGS) on local hair growth promotion and systemic absorption of topically applied minoxidil in a mouse model. [2005.12.08]
Influence of minoxidil on ischemic cutaneous flaps in rats. [2005.11]
Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution. [2005.07]
Other possibly related research studies
A model of orthostatic hypotension in the conscious monkey using lower body negative pressure. [2006.09]
Alopecia areata masquerading as frontal fibrosing alopecia. [2006.02]
Recent findings with computerized methods for scalp hair growth measurements. [2005.12]
Frontal fibrosing alopecia: a survey in 16 patients. [2005.11]
Psychological effect, pathophysiology, and management of androgenetic alopecia in men. [2005.10]
Alopecia areata: what to expect from current treatments. [2005.09]
Effective treatment of female androgenic alopecia with dutasteride. [2005.09]
Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes. [2005.07.14]
Androgenetic alopecia and current methods of treatment. [2005.03]
Non surgical therapy for anal fissure. [2006.10.18]
Protection against chemotherapy-induced alopecia. [2006.11]
Efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus: a prospective case series--a non-controlled, open-label study. [2006]
Pathological circumstances impair the ability of "dark" neurons to undergo spontaneous recovery. [2006.09.19]
[Resistant hypertension and paradox effect in patient with hemodialysis treatment] [2006.03]
Usage of pain medications during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP). [2005.09]
Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. [2005.12.15]
Treatment of hypertension in chronic kidney disease. [2005.11]
A proposal for a national program reporting beneficial drug responses, analogous to the existing program to detect adverse drug responses. [2006]
Treatment of female pattern hair loss with oral antiandrogens. [2005.03]
Congenital alopecia areata. [2005.02]
Evolution of techniques in hair transplantation: a 12-year perspective. [2007.02]
Effects of the treatment with glibenclamide, an ATP-sensitive potassium channel blocker, on intestinal ischemia and reperfusion injury. [2007.02.05]
Alopecia areata. [2007.02]
Androgenetic alopecia. [2007.06]
[Arterial hypertension in renal transplant recipients] [2007.04]
Female pattern hair loss: current treatment concepts. [2007]
Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. [2008.01]
Improving care in resistant hypertension: medication trends and nonpharmacologic strategies in a specialty clinic. [2007]
Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog. [2007.09]
Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. [2007.12.01]
Associations between sympathetic activity, plasma concentrations of renin, aldosterone, and parathyroid hormone, and the degree of intractability of blood pressure control in modialysis patients. [2007.08]
Interventions for alopecia areata. [2008.04.16]
Development and evaluation of polyherbal formulation for hair growth-promoting activity. [2007.06]
[Hair follicle regeneration] [2008.05]
Adolescent hair loss. [2008.08]
[Arterial hypertension - dosing recommendations at beginning and end of treatment] [2008.10]
Treatment of persistent alopecia areata with sulfasalazine. [2008.08]
Recent advances in the pharmacotherapy of chronic anal fissure: an update. [2008.07]
Hair transplantation for men. [2008.09]
Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models. [2008.08.28]
Hair growth promoting activity of Eclipta alba in male albino rats. [2008.08]
In vivo hair growth promotion effects of cosmetic preparations containing hinokitiol-loaded poly(epsilon-caprolacton) nanocapsules. [2008.08]
Diagnosing and treating hair loss. [2009.08.15]
Alopecia secondary to mesotherapy. [2009.10]
Potassium channels in health, disease & development of channel modulators. [2009.03]
The use of low-level light for hair growth: part I. [2009.06]
Androgens and hair loss. [2009.06]
Dermatologic medication in pregnancy. [2009]
Hair loss in women. [2009.03]
Alopecia areata: evidence-based treatments. [2009.03]
Chemotherapy-induced alopecia. [2009.03]
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival. [2009.01.14]
Chemotherapy-induced hair loss. [2010.07]
Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. [2010.09]
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. [2010.07]
Finasteride treatment of hair loss in women. [2010.06]
Male androgenetic alopecia. [2010.06]
Hair restoration in the ethnic patient and review of hair transplant fundamentals. [2010.02]
Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. [2010.01]
Alopecia areata update: part II. Treatment. [2010.02]
|